Thank you for sharing!

Your article was successfully shared with the contacts you provided.
The news that Biogen, Inc., and IDEC Pharmaceuticals Corporation plan to merge brought back memories of the heady late nineties. Not only is the $6.8 billion biotechnology deal structured as a stock swap; it’s also a merger of equals. Shareholders of San Diego�based IDEC will own 50.5 percent of the combined company, while Biogen shareholders will own 49.5 percent. The deal was announced June 23. Biogen IDEC Inc., the new company’s proposed name, will retain Biogen’s current headquarters in Cambridge, Massachusetts, and be led by Biogen CEO and chairman James Mullen. IDEC chairman William Rastetter will be the combined company’s executive chairman. The new company will have two drugs with annual sales of more than $1 billion each: Avonex, the multiple sclerosis treatment, and Rituxan, a drug for non-Hodgkin’s lymphoma. The deal must be approved by both companies’ stockholders as well as various regulators. Biogen and IDEC hope to close the deal this fall. For merger partner IDEC Pharmaceuticals Corporation (San Diego) In-house: General counsel John Dunn, corporate counsel Jo Ann Taormina, and intellectual property counsel Chris Dayton. Dunn joined IDEC in 2001 from Pillsbury Winthrop, where he had been a partner. Taormina was also formerly with Pillsbury. Pillsbury Winthrop (San Francisco): M&A: T. Michael Hird, David Snyder, and associates Justin Ferber, Chris Forrester, and Clara Liang. Intellectual property: John Wetherell, Jr. Tax: James Chudy and C. Brian Wainwright. Employee benefits: Peter Hunt. Antitrust: counsel Aileen “Chucca” Meyer. (Hird, Snyder, Ferber, Forrester and Wetherell are in San Diego; Liang, Chudy, and Hunt are in New York; Wainwright is in Palo Alto; and Meyer is in Washington, D.C.) Pillsbury has represented IDEC since 1999. For merger partner Biogen, Inc. (Cambridge, Massachusetts) In-house: General counsel Thomas Bucknum and chief corporate counsel Ann Marie Cook. Skadden, Arps, Slate, Meagher & Flom (New York): M&A: Roger Aaron, Kent Coit, Louis Goodman, and associate Margaret Cohen. (Coit, Goodman, and Cohen are in Skadden’s Boston office.)

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at [email protected]


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.